Latest News and Press Releases

- Pivotal Phase 3 data for the treatment of Pachyonychia Congenita anticipated mid-2023 - - Phase 2 data for the treatment of Microcystic Lymphatic Malformations anticipated March 2023 - - Phase 2b...

Led by new investor Petrichor, with participation from new and existing investors Lead product candidate, QTORIN™ rapamycin, in late-stage clinical development for serious, rare genetic skin diseases...

~ VALO Study Misses Primary Endpoint in Phase 3 Randomized Withdrawal Portion ~ ~ VALO Study Achieves Primary Endpoint in Phase 2 Open-Label Portion ~ ~ Palvella Plans to Share Results with the U.S....

Investor Syndicate Comprised of Leading Biotech Investors Proceeds to Accelerate Pipeline of Rare Disease Therapies, Including Late-Stage Programs in Pachyonychia Congenita and Gorlin Syndrome ...

Wayne, PA , March 06, 2020 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...

Wayne, PA, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare-disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...

Wayne, PA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...

Wayne, PA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...

Wayne, PA, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...

Wayne, PA, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...